|
1
|
Dimaras H, Kimani K, Dimba EA, et al:
Retinoblastoma. Lancet. 379:1436–1446. 2012. View Article : Google Scholar
|
|
2
|
Bai S, Ren R, Li B, et al: Delay in the
diagnosis of retinoblastoma in China. Acta Ophthalmol. 89:e72–74.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
MacCarthy A, Draper GJ, Steliarova-Foucher
E and Kingston JE: Retinoblastoma incidence and survival in
European children (1978–1997). Report from the Automated Childhood
Cancer Information System project. Eur J Cancer. 42:2092–2102.
2006.
|
|
4
|
Gallie BL, Zhao J, Vandezande K, White A
and Chan HS: Global issues and opportunities for optimized
retinoblastoma care. Pediatr Blood Cancer. 49:1083–1090. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Houston SK, Murray TG, Wolfe SQ and
Fernandes CE: Current update on retinoblastoma. Int Ophthalmol
Clin. 51:77–91. 2011. View Article : Google Scholar
|
|
6
|
Radhakrishnan V, Kashyap S, Pushker N, et
al: Outcome, pathologic findings and compliance in orbital
retinoblastoma (International Retinoblastoma Staging System stage
III) treated with neoadjuvant chemotherapy: a prospective study.
Ophthalmology. 119:1470–1477. 2012. View Article : Google Scholar
|
|
7
|
Pica A, Moeckli R, Balmer A, et al:
Preliminary experience in treatment of papillary and macular
retinoblastoma: evaluation of local control and local complications
after treatment with linear accelerator-based stereotactic
radiotherapy with micromultileaf collimator as second-line or
salvage treatment after chemotherapy. Int J Radiat Oncol Biol Phys.
81:1380–1386. 2011.
|
|
8
|
Wilson MW, Fraga CH, Rodriguez-Galindo C,
Hagedorn N, Leggas ML and Stewart C: Expression of the multi-drug
resistance proteins and the pregnane X receptor in treated and
untreated retinoblastoma. Curr Eye Res. 34:386–394. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rutella S, Iudicone P, Bonanno G, et al:
Adoptive immunotherapy with cytokine-induced killer cells generated
with a new good manufacturing practice-grade protocol. Cytotherapy.
14:841–850. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Campoli M, Ferris R, Ferrone S and Wang X:
Immunotherapy of malignant disease with tumor antigen-specific
monoclonal antibodies. Clin Cancer Res. 16:11–20. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Leffers N, Daemen T, Helfrich W, et al:
Antigen-specific active immunotherapy for ovarian cancer. Cochrane
Database Syst Rev. CD0072872010.
|
|
12
|
Palucka K, Ueno H, Fay J and Banchereau J:
Dendritic cells and immunity against cancer. J Intern Med.
269:64–73. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cella M, Sallusto F and Lanzavecchia A:
Origin, maturation and antigen presenting function of dendritic
cells. Curr Opin Immunol. 9:10–16. 1997. View Article : Google Scholar
|
|
14
|
de Vleeschouwer S, Rapp M, Sorg RV, et al:
Dendritic cell vaccination in patients with malignant gliomas:
current status and future directions. Neurosurgery. 59:988–999.
2006.PubMed/NCBI
|
|
15
|
Schnurr M, Galambos P, Scholz C, et al:
Tumor cell lysate-pulsed human dendritic cells induce a T-cell
response against pancreatic carcinoma cells: an in vitro model for
the assessment of tumor vaccines. Cancer Res. 61:6445–6450.
2001.
|
|
16
|
Wu YG, Wu GZ, Wang L, Zhang YY, Li Z and
Li DC: Tumor cell lysate-pulsed dendritic cells induce a T cell
response against colon cancer in vitro and in vivo. Med Oncol.
27:736–742. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mesiano G, Todorovic M, Gammaitoni L, et
al: Cytokine-induced killer (CIK) cells as feasible and effective
adoptive immunotherapy for the treatment of solid tumors. Expert
Opin Biol Ther. 12:673–684. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shi L, Zhou Q, Wu J, et al: Efficacy of
adjuvant immunotherapy with cytokine-induced killer cells in
patients with locally advanced gastric cancer. Cancer Immunol
Immunother. 61:2251–2259. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang J, Zhu L, Wei J, et al: The effects
of cytokine-induced killer cells for the treatment of patients with
solid tumors: a clinical retrospective study. J Cancer Res Clin
Oncol. 138:1057–1062. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhan HL, Gao X, Pu XY, et al: A randomized
controlled trial of postoperative tumor lysate-pulsed dendritic
cells and cytokine-induced killer cells immunotherapy in patients
with localized and locally advanced renal cell carcinoma. Chin Med
J (Engl). 125:3771–3777. 2012.
|
|
21
|
Yang L, Ren B, Li H, et al: Enhanced
antitumor effects of DC-activated CIKs to chemotherapy treatment in
a single cohort of advanced non-small-cell lung cancer patients.
Cancer Immunol Immunother. Jun 29–2012.(Epub ahead of print).
|
|
22
|
Zhong R, Teng J, Han B and Zhong H:
Dendritic cells combining with cytokine-induced killer cells
synergize chemotherapy in patients with late-stage non-small cell
lung cancer. Cancer Immunol Immunother. 60:1497–1502. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Komada Y, Zhang SL, Zhou YW, et al:
Cellular immunosuppression in children with acute lymphoblastic
leukemia: effect of consolidation chemotherapy. Cancer Immunol
Immunother. 35:271–276. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mackall CL: T-cell immunodeficiency
following cytotoxic antineoplastic therapy: a review. Stem Cells.
18:10–18. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schmidt-Wolf IG, Lefterova P, Mehta BA, et
al: Phenotypic characterization and identification of effector
cells involved in tumor cell recognition of cytokine-induced killer
cells. Exp Hematol. 21:1673–1679. 1993.PubMed/NCBI
|
|
26
|
Pletinckx K, Stijlemans B, Pavlovic V, et
al: Similar inflammatory DC maturation signatures induced by TNF or
Trypanosoma brucei antigens instruct default Th2-cell responses.
Eur J Immunol. 41:3479–3494. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Puri RK and Leland P: Systemic
administration of recombinant interleukin-6 in mice induces
proliferation of lymphoid cells in vivo. Lymphokine Cytokine Res.
11:133–139. 1992.PubMed/NCBI
|
|
28
|
Buelens C, Willems F, Delvaux A, et al:
Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86)
expression on human peripheral blood dendritic cells. Eur J
Immunol. 25:2668–2672. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kulkarni AB, Mullbacher A and Blanden RV:
Functional analysis of macrophages, B cells and splenic dendritic
cells as antigen-presenting cells in West Nile virus-specific
murine T lymphocyte proliferation. Immunol Cell Biol. 69:71–80.
1991. View Article : Google Scholar
|
|
30
|
Hasel T, Yoshimura R, Wada S and Chargui
J: Dendritic cells, generated in vitro, are immunocompetent and
very useful in the induction of specific cytotoxic T lymphocyte
activity. Transplant Proc. 33:3814–3815. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lu PH and Negrin RS: A novel population of
expanded human CD3+CD56+ cells derived from T
cells with potent in vivo antitumor activity in mice with severe
combined immunodeficiency. J Immunol. 153:1687–1696.
1994.PubMed/NCBI
|
|
32
|
Wang FS, Liu MX, Zhang B, et al: Antitumor
activities of human autologous cytokine-induced killer (CIK) cells
against hepatocellular carcinoma cells in vitro and in vivo. World
J Gastroenterol. 8:464–468. 2002.PubMed/NCBI
|
|
33
|
Ma Y, Zhang Z, Tang L, et al:
Cytokine-induced killer cells in the treatment of patients with
solid carcinomas: a systematic review and pooled analysis.
Cytotherapy. 14:483–493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Alvarnas JC, Linn YC, Hope EG and Negrin
RS: Expansion of cytotoxic CD3+ CD56+ cells
from peripheral blood progenitor cells of patients undergoing
autologous hematopoietic cell transplantation. Biol Blood Marrow
Transplant. 7:216–222. 2001.PubMed/NCBI
|
|
35
|
Baker J, Verneris MR, Ito M, Shizuru JA
and Negrin RS: Expansion of cytolytic CD8(+) natural killer T cells
with limited capacity for graft-versus-host disease induction due
to interferon gamma production. Blood. 97:2923–2931. 2001.
|
|
36
|
Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume
KG and Weissman IL: Use of a SCID mouse/human lymphoma model to
evaluate cytokine-induced killer cells with potent antitumor cell
activity. J Exp Med. 174:139–149. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Leemhuis T, Wells S, Scheffold C, Edinger
M and Negrin RS: A phase I trial of autologous cytokine-induced
killer cells for the treatment of relapsed Hodgkin disease and
non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 11:181–187.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang YS, Yuan FJ, Jia GF, et al: CIK
cells from patients with HCC possess strong cytotoxicity to
multidrug-resistant cell line Bel-7402/R. World J Gastroenterol.
11:3339–3345. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jiang JT, Shen YP, Wu CP, et al:
Increasing the frequency of CIK cells adoptive immunotherapy may
decrease risk of death in gastric cancer patients. World J
Gastroenterol. 16:6155–6162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen J, Huang X, Huang G, Chen Y, Chen L
and Song H: Preconditioning chemotherapy with cisplatin enhances
the antitumor activity of cytokine-induced killer cells in a murine
melanoma model. Cancer Biother Radiopharm. 27:210–220. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Su X, Zhang L, Jin L, et al: Immunotherapy
with cytokine-induced killer cells in metastatic renal cell
carcinoma. Cancer Biother Radiopharm. 25:465–470. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hongeng S, Petvises S, Worapongpaiboon S,
Rerkamnuaychoke B, Pakakasama S and Jootar S: Generation of
CD3+ CD56+ cytokine-induced killer cells and
their in vitro cytotoxicity against pediatric cancer cells. Int J
Hematol. 77:175–179. 2003.
|
|
43
|
Verneris MR, Arshi A, Edinger M, et al:
Low levels of Her2/neu expressed by Ewing’s family tumor cell lines
can redirect cytokine-induced killer cells. Clin Cancer Res.
11:4561–4570. 2005.PubMed/NCBI
|
|
44
|
Wang QJ, Wang H, Pan K, et al: Comparative
study on anti-tumor immune response of autologous cytokine-induced
killer (CIK) cells, dendritic cells-CIK (DC-CIK) and
semi-allogeneic DC-CIK. Chin J Cancer. 29:641–648. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shi SB, Ma TH, Li CH and Tang XY: Effect
of maintenance therapy with dendritic cells: cytokine-induced
killer cells in patients with advanced non-small cell lung cancer.
Tumori. 98:314–319. 2012.PubMed/NCBI
|
|
46
|
Yang XJ, Huang JA, Lei W, Zhu YB and Zhang
XG: Antitumor effects of cocultured dendritic cells and
cytokine-induced killer cells on lung cancer in vitro and in vivo.
Ai Zheng. 25:1329–1333. 2006.PubMed/NCBI
|
|
47
|
Tan G, Zhang X, Feng H, Luo H and Wang Z:
The therapeutic effect of cytokine-induced killer cells on
pancreatic cancer enhanced by dendritic cells pulsed with K-ras
mutant peptide. Clin Dev Immunol. 2011:6493592011.PubMed/NCBI
|
|
48
|
Coughlin CM, Vance BA, Grupp SA and
Vonderheide RH: RNA-transfected CD40-activated B cells induce
functional T-cell responses against viral and tumor antigen
targets: implications for pediatric immunotherapy. Blood.
103:2046–2054. 2004. View Article : Google Scholar
|
|
49
|
Yufeng D, Guocheng Z, Dongliang X, et al:
Whole-tumor-antigen-pulsed dendritic cells elicit cytotoxic T-cell
response against pediatric nasopharyngeal carcinoma in vitro. Med
Oncol. 26:78–85. 2009. View Article : Google Scholar
|
|
50
|
Holsti MA and Raulet DH: IL-6 and IL-1
synergize to stimulate IL-2 production and proliferation of
peripheral T cells. J Immunol. 143:2514–2519. 1989.PubMed/NCBI
|
|
51
|
Lin G, Wang J, Lao X, et al: Interleukin-6
inhibits regulatory T cells and improves the proliferation and
cytotoxic activity of cytokine-induced killer cells. J Immunother.
35:337–343. 2012. View Article : Google Scholar : PubMed/NCBI
|
